MedPath

The Effectiveness of Hyperbaric Oxygen Therapy on Pneumonia Complicating Stroke

Not Applicable
Conditions
Stroke
Pneumonia
Hyperbaric Oxygen Therapy
Interventions
Procedure: hyperbaric oxygen therapy
Registration Number
NCT04376359
Lead Sponsor
Ya Zhang
Brief Summary

To investigate the evidence for the integration of hyperbaric oxygen therapy (HBOT) as part of interdisciplinary stroke rehabilitation.

Detailed Description

Pneumonia complicating stroke is very difficult to manage and has a very poor prognosis, leading to a significantly higher risk of death. Oral opportunistic pathogens have been reported to be associated with the incidence of pneumonia among non-stroke immunocompromised subjects. Preliminary studies found that patients with stroke had higher carriage rates of oral opportunistic pathogens than healthy subjects. Therefore, investigators hypothesize that pneumonia complicating stroke is associated with oral opportunistic pathogens, and hyperbaric oxygen therapy may reduce the incidence of pneumonia complicating stroke by increasing the flow of saliva, which can affect the species and relative abundance of oral opportunistic pathogens. In order to prove this, investigators need to (1) firstly conduct a randomized controlled trial to confirm whether hyperbaric oxygen therapy is able to reduce the levels of plaque, and the incidence of pneumonia complicating stroke at clinical level; (2) secondly employ metagenomics analysis to compare oral rinse samples and respiratory samples, and to identify pneumonia-associated "oral opportunistic pathogens group"; (3) finally elucidate how hyperbaric oxygen therapy influences the species and relative abundance of oral opportunistic pathogens. This proposed study will provide evidence for the integration of hyperbaric oxygen therapy as part of interdisciplinary stroke rehabilitation.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
168
Inclusion Criteria
  • New stroke events within 1-3 months (confirmed by CT and MRI)
  • Moderate to severe disability (Barthel Index < 70)
  • The patient is conscious, breathing autonomously, not undergoing tracheotomy or tracheal intubation for ventilator-assisted respiration
  • No concurrent lower respiratory infections and other lung diseases
  • The condition is relatively stable
  • Cognitive function is normal to moderately impaired (Mini-Physical State Exchange, MMSE score>18)
  • The Gugging Swallowing Screen (GUSS) shows swallowing difficulties
  • No systemic and local use of antibiotic-containing mouthwash
Exclusion Criteria
  • A mild disability (Barthel Index > 70)
  • The swallowing function is normal
  • Indwelling nasogastric feeding tube
  • The neurological status of the patient was significantly dynamically altered (significantly improved or worsened) in the short term prior to inclusion in the trial
  • The patient had been treated with hyperbaric oxygen for other indications
  • Had a chest condition and cannot withstand the pressure changes caused by hyperbaric oxygen therapy
  • Have an inner ear disease
  • Claustrophobia
  • Communication barriers and inability to give informed consent

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
hyperbaric oxygen therapyhyperbaric oxygen therapyPatients with stroke will receive the hyperbaric oxygen therapy (HBOT) for 40 times, which were completed on 40 business days over a 2-month period and each session lasted 90 minutes at 100% oxygen concentration and 2 atmospheres.
Primary Outcome Measures
NameTimeMethod
Incidence of pneumonia2 months

To calculate and compare the incidence of pneumonia between interventional group and control group, to identify whether the intervention approach could reduce the incidence.

Metagenomics2 months

To analyze and compare the effect of intervention on the diversity of bacteria in saliva samples and lower respiratory sputum samples.

Secondary Outcome Measures
NameTimeMethod
Short Form Health Survey 12 (SF-12)2 months

The concise health status scale (SF-12) IS used to assess the systemic health-related quality of life in stroke patients. It covers eight different areas: general health (GH), physical functioning (PF), bodily pain (BP), role-physical (RP), mental health (MH), vitality (VT), social functioning (SF), role-emotional (RE). The SF-12 consists of 12 items, and each of them has its own physical component summary (PCS) and mental component summary (MCS) regression coefficients. The response to each item will be multiplied by its PCS regression coefficient and added together with the PCS constant to provide Physical Health summary scores (SF-12 PCS). Mental Health summary scores (SF-12 MCS) will be calculated likewise. The higher the score, the higher the quality of life.

Trial Locations

Locations (1)

The Second People's Hospital of Hefei

🇨🇳

Hefei, Anhui, China

© Copyright 2025. All Rights Reserved by MedPath